Tissue Regenix Group plc

Equities

TRX

GB00BNTXR104

Advanced Medical Equipment & Technology

Delayed London S.E. 04:56:10 2024-03-28 am EDT 5-day change 1st Jan Change
62.7 GBX -0.48% Intraday chart for Tissue Regenix Group plc -1.26% +20.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tissue Regenix annual loss narrows sharply as revenue jumps AN
Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports FY23 Revenue $29.5M MT
Earnings Flash (TRX.L) TISSUE REGENIX GROUP Posts FY23 Loss $-0.02 MT
Tissue Regenix Group plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tissue Regenix ships first allograft products order AN
Tissue Regenix Group plc Signs Two New Distributor Agreements for its Allograft Products in Turkey and Ireland CI
Treatt revenue falls; Secure Trust profit picks up AN
Solid State expects higher annual revenue AN
Tissue Regenix Inks Distribution Deal for Allograft Products in Spain MT
Tissue Regenix Gets Regulatory Nod for Irish Logistics Hub MT
Tissue Regenix Group plc Announces HPRA approval & distribution agreement in Spain CI
FTSE 100 Closes Down 0.2% Despite Rebound Driven by Energy Stocks DJ
Sterling Weakens as China Concerns Grow DJ
Tissue Regenix loss narrows on higher revenue; launches BioRinse AN
Earnings Flash (TRX.L) TISSUE REGENIX GROUP Posts H1 Revenue $14.1M MT
Earnings Flash (TRX.L) TISSUE REGENIX GROUP Posts H1 Loss $-0.01 MT
Tissue Regenix Group plc Announces the Launch of its New BioRinse® Product Line for All Sports Medicine Allografts CI
Tissue Regenix Group plc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
FTSE 100 Closes Monday Down 0.4% Dragged by Miners DJ
Beacon sees delays; Churchill China trades in line AN
UK Finance Chiefs Are More Gloomy About Outlook DJ
Tissue Regenix signs exclusive distribution deal with Joint Operations AN
Tissue Regenix Signs Exclusive Distribution Agreement with Joint Operations Ltd CI
Tissue Regenix signs multi-year distribution contract AN
Tissue Regenix Group plc Announces Multi-Year Distribution Agreement with Australian Allografts CI
Chart Tissue Regenix Group plc
More charts
Tissue Regenix Group plc is a United Kingdom-based international medical technology company. The Company is focused on the development of regenerative products utilizing its two platform technologies, such as dCell and BioRinse. The dCell platform addresses soft tissue needs and BioRinse platform provides sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. Its dCell technology removes deoxyribonucleic acid (DNA) and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold, which is not rejected by the patient's body and can then be used to repair diseased or damaged body parts. Its BioRinse technology is primarily utilized to provide a natural bone filler solution, tested for osteoinductivity, which can stimulate and regenerate native bone growth. Its CellRight Technologies is engaged in the development of osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Tissue Regenix Group plc - London S.E.
  4. News Tissue Regenix Group plc
  5. Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports H1 Loss $-0.00